Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Glyburide

FDA-approved product (tablet, oral), marketed as Diabeta, Glyburide, Glyburide (Micronized) and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Glyburide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonylureas
FDA pharmacologic class
Sulfonylurea FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Glyburide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Glyburide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes

    NCT00035568 · start 2002-02

    Registered record
    Registry ID
    NCT00035568
    Conditions
    Diabetes Mellitus, Non-Insulin-Dependent
    Interventions
    Glucovance (metformin HCl/glyburide); or Metformin HCl alone; or Glyburide alone.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-02
    Completion
    2003-06
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Non-Insulin-Dependent
    InterventionGlucovance (metformin HCl/glyburide); or Metformin HCl alone; or Glyburide alone.
    PhasePhase 4
    Registry statusCompleted

  • Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes

    NCT00549874 · start 2002-02

    Registered record
    Registry ID
    NCT00549874
    Conditions
    Type 2 Diabetes
    Interventions
    Rosiglitazone; Glyburide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2002-02
    Completion
    2006-11
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionRosiglitazone; Glyburide
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease

    NCT00521742 · start 2001-03

    Registered record
    Registry ID
    NCT00521742
    Conditions
    Diabetes Mellitus
    Interventions
    Pioglitazone; Glyburide; Pioglitazone; Glyburide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-03
    Completion
    2003-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus
    InterventionPioglitazone; Glyburide; Pioglitazone; Glyburide
    PhasePhase 3
    Registry statusCompleted

  • Safety Study of Pioglitazone Compared To Glyburide on Liver Function

    NCT00494312 · start 2000-10

    Registered record
    Registry ID
    NCT00494312
    Conditions
    Diabetes Mellitus; Liver
    Interventions
    Pioglitazone; Glyburide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-10
    Completion
    2005-06
    Enrolment
    2,120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus; Liver
    InterventionPioglitazone; Glyburide
    PhasePhase 4
    Registry statusCompleted

  • Preferred Treatment of Type 1.5 Diabetes

    NCT00194896 · start 2000-02

    Registered record
    Registry ID
    NCT00194896
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    rosiglitazone; glyburide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2000-02
    Completion
    2008-12
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    Interventionrosiglitazone; glyburide
    PhaseNot applicable
    Registry statusCompleted